Cabaletta Bio, Inc.
cabalettabio.comWhat Do They Do?
Develops engineered T-cell therapies for people with autoimmune diseases, led by rese-cel, an experimental treatment being tested across several conditions.
10-K for FY2025, filed Mar 23, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 13, 2026
−$51MView ↗
- ▲ +13% (Loss)
- vs −$45.1M in Q2 FY2025
-
Sep 14, 2026
Warrant exercises brought in approximately $128.2 million
Exercises from July 1 through the expiration date generated approximately $115.0 million in gross proceeds.
Sources
8-K, filed Sep 14, 2026
In connection with Cabaletta Bio’s (the “Corporation”) June 2025 underwritten public offering, the Corporation issued 53,090,190 common…View ↗
-
May 4, 2026
Cabaletta priced a $150 million stock offering
The company estimated approximately $141 million in net proceeds to fund rese-cel development and operations into mid-2027.
Sources
8-K, filed May 4, 2026
Cabaletta Bio Announces Pricing of $150 Million Underwritten OfferingView ↗
From two strategies to CARTA
The older report described both CARTA and CAART strategies, with candidates targeting all B cells or disease-causing B cells. The latest report centers the platform on CARTA and identifies rese-cel as its lead candidate.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 23, 2026
Who Do They Compete With?
Competes with Novartis Pharmaceuticals, Gilead Sciences, Bristol Myers Squibb, Johnson and Johnson, Legend Biotech, and Autolus
10-K for FY2025, filed Mar 23, 2026There are multiple companies with marketed CAR T therapies for the treatment of hematologic cancers, including Novartis Pharmaceuticals…View ↗
Loading...
